IP Library Granted Patent US 7,691,821
Granted Patent B2
US 7,691,821 · App. 10/709,801 · Granted Apr 6, 2010

Inhibition of SHIP to enhance stem cell harvest and transplantation

Assignee: University of South Florida
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,691,821
App. No.
10/709,801
Granted
Apr 6, 2010
Kind
B2
Abstract

The instant invention teaches the inhibition of SHIP expression, or function, for the increased efficacy of autologous stem cell transplants. In another embodiment, interference with SHIP function can be used to temporarily expand and mobilize the hematopoietic stem cell compartment to assist with leukapheresis, to promote hematopoietic recovery after myeloablation treatments, to deplete target stem cell clones (such a leukemic clones and other tumor stem cell types), and to deplete, or damage, the repopulating ability of the endogenous hematopoietic stem cell pool in order to allow transplanted hematopoietic stem cells to better home and engraft and to promote in vivo expansion and mobilization of other organ-specific stem cell populations (e.g., mesenchymal, mammary).

Claims (10)

1. A method of increasing the number of hematopoietic stem cells in peripheral blood of a patient, comprising administering an effective amount of an RNA interference molecule targeting SH2-domain containing inositol 5-phosphatase (SHIP) to the patient, wherein the number of hematopoietic stem cells in the peripheral blood of the patient is thereby increased.

2. The method of claim 1 , further comprising harvesting the hematopoietic stem cells from the patient after said administering.

3. The method of claim 2 , wherein said harvesting comprises leukopheresis.

4. The method of claim 2 , further comprising administering the harvested hematopoietic stem cells to the patient.

5. The method of claim 1 , wherein the RNA interference molecule is administered intravenously.

6. The method of claim 1 , wherein said administering mobilizes the hematopoietic stem cells to the peripheral blood.

7. The method of claim 1 , wherein the patient has undergone myeloablation prior to said administering.

8. The method of claim 1 , wherein the RNA interference molecule is administered to the patient for 1 week or 2 weeks.

9. The method of claim 1 , wherein the subject has cancer or an autoimmune deficiency.

10. The method of claim 4 , wherein the subject has cancer or an autoimmune deficiency.

Assignments (4)
CONFIRMATORY LICENSE Recorded Jun 30, 2016
From: UNIVERSITY OF SOUTH FLORIDA
To: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT
Reel/Frame 039217/0808 →
CONFIRMATORY LICENSE Recorded Feb 11, 2015
From: UNIVERSITY OF SOUTH FLORIDA
To: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT
Reel/Frame 034955/0020 →
CONFIRMATORY LICENSE Recorded May 24, 2010
From: UNIVERSITY OF SOUTH FLORIDA
To: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT
Reel/Frame 024427/0498 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 23, 2004
From: DESPONTS, CAROLINE; WAHLE, JOSEPH; NINOS, JOHN; KERR, WILLIAM G.
To: UNIVERSITY OF SOUTH FLORIDA
Reel/Frame 014887/0855 →
Continuity (3)
Continuation In Part 0995517400 · Sep 19, 2001
Provisional Application 6032023300 · May 28, 2003
Related Publication 20060223749A1 · Oct 5, 2006